Your comparisons are meaningless, as FY14 is history and almost a different company. MCP has divested under-performing businesses and stock lines, moving to higher quality growth items such as new lines in health and beauty products, hence reducing revenue. Underlying earnings per share is up around 10% and EBIT is up around 14% on much lower revenues. That is a quality result which should continue in FY17.
MCP Price at posting:
$1.06 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)